Guidant (GDT) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Guidant (GDT)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: B4TheBell who wrote (76)	12/23/1997 10:48:00 AM
From: JMS	Read Replies (1) of 235

The only impact will be in net income, not in earnings before charges, which is how the "analysts" measure growth. Of course these are the same analysts that figured out that sales in Japan would not affect earnings, a country with one of the lowest rates of heart disease/problems in the world. EVTI is a good, good buy for GDT. I've been hearing whispers that the market share of the multi-link is much higher than 50%. Could be a nice Feb 3rd. The only bump in the road is the pending approval of the AVEI stent. The thing is that facilities are going toward bundling products. AVEI is a one trick pony, and GDT is not. Hopefully GDT can maintain market share in spite of increased competition.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next